developed a MET-targeted crizotinib-based PROTAC, PRO-6E (Figure 32), which demonstrated high efficacy in vitro and in vivo, significantly inhibiting proliferation (IC50 = 0.347 μM) and motility in MET-positive gastric cancer (GC) cells and showing strong antitumor effects in the MKN-45 xenograft model. The gene discussed is MET; the disease is gastric cancer.